1	4	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Discussion	_	_	NN	_	_	_	_	_


1	Diet	_	_	NN	_	_	_	_	_
2	interventions	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	well-established	_	_	JJ	_	_	_	_	_
5	strategies	_	_	NNS	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	reduce	_	_	VB	_	_	_	_	_
8	body	_	_	NN	_	_	_	_	_
9	weight	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	improve	_	_	VB	_	_	_	_	_
12	glucose	_	_	NN	_	_	_	_	_
13	metabolism	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	however	_	_	RB	_	_	_	_	_
16	no	_	_	DT	_	_	_	_	_
17	evidence	_	_	NN	_	_	_	_	_
18	exists	_	_	VBZ	_	_	_	_	_
19	about	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	effects	_	_	NNS	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	periodic	_	_	JJ	_	_	_	_	_
24	fasting	_	_	NN	_	_	_	_	_
25	on	_	_	IN	_	_	_	_	_
26	NAFLD	_	_	NNP	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	study	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	first	_	_	JJ	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	show	_	_	VB	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	beneficial	_	_	JJ	_	_	_	_	_
10	effects	_	_	NNS	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	periodic	_	_	JJ	_	_	_	_	_
13	fasting	_	_	VBG	_	_	_	_	_
14	on	_	_	IN	_	_	_	_	_
15	fatty	_	_	JJ	_	_	_	_	_
16	liver	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	results	_	_	NNS	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	our	_	_	PRP$	_	_	_	_	_
5	study	_	_	NN	_	_	_	_	_
6	supported	_	_	VBD	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	hypothesis	_	_	NN	_	_	_	_	_
9	that	_	_	IN	_	_	_	_	_
10	FLI	_	_	NNP	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	surrogate	_	_	JJ	_	_	_	_	_
14	parameter	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	fatty	_	_	JJ	_	_	_	_	_
17	liver	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	significantly	_	_	RB	_	_	_	_	_
20	decreases	_	_	VBZ	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	individuals	_	_	NNS	_	_	_	_	_
23	with	_	_	IN	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	without	_	_	IN	_	_	_	_	_
26	T2DM	_	_	NNP	_	_	_	_	_
27	after	_	_	IN	_	_	_	_	_
28	a	_	_	DT	_	_	_	_	_
29	fasting	_	_	VBG	_	_	_	_	_
30	intervention	_	_	NN	_	_	_	_	_
31	of	_	_	IN	_	_	_	_	_
32	at	_	_	IN	_	_	_	_	_
33	least	_	_	JJS	_	_	_	_	_
34	6	_	_	CD	_	_	_	_	_
35	days	_	_	NNS	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	prospective	_	_	JJ	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	design	_	_	NN	_	_	_	_	_
5	according	_	_	VBG	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	standardized	_	_	VBN	_	_	_	_	_
9	protocol	_	_	NN	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	well-established	_	_	JJ	_	_	_	_	_
13	fasting	_	_	NN	_	_	_	_	_
14	technique	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	close	_	_	JJ	_	_	_	_	_
18	clinical	_	_	JJ	_	_	_	_	_
19	monitoring	_	_	NN	_	_	_	_	_
20	was	_	_	VBD	_	_	_	_	_
21	a	_	_	DT	_	_	_	_	_
22	strength	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	this	_	_	DT	_	_	_	_	_
25	study	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Weight	_	_	NN	_	_	_	_	_
2	reduction	_	_	NN	_	_	_	_	_
3	and	_	_	CC	_	_	_	_	_
4	improvement	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	fatty	_	_	JJ	_	_	_	_	_
7	liver	_	_	NN	_	_	_	_	_
8	indicators	_	_	NNS	_	_	_	_	_
9	are	_	_	VBP	_	_	_	_	_
10	known	_	_	VBN	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	be	_	_	VB	_	_	_	_	_
13	interrelated	_	_	VBN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	results	_	_	NNS	_	_	_	_	_
3	indicate	_	_	VBP	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	even	_	_	RB	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	modest	_	_	JJ	_	_	_	_	_
8	reduction	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	BMI	_	_	NN	_	_	_	_	_
11	improved	_	_	VBN	_	_	_	_	_
12	surrogate	_	_	JJ	_	_	_	_	_
13	markers	_	_	NNS	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	fatty	_	_	JJ	_	_	_	_	_
16	liver	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Indeed	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	nearly	_	_	RB	_	_	_	_	_
5	half	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	subjects	_	_	NNS	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	highest	_	_	JJS	_	_	_	_	_
12	risk	_	_	NN	_	_	_	_	_
13	category	_	_	NN	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	FLI	_	_	NNP	_	_	_	_	_
16	>	_	_	SYM	_	_	_	_	_
17	60	_	_	CD	_	_	_	_	_
18	)	_	_	-RRB-	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	a	_	_	DT	_	_	_	_	_
21	BMI	_	_	NN	_	_	_	_	_
22	reduction	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	less	_	_	JJR	_	_	_	_	_
25	than	_	_	IN	_	_	_	_	_
26	5	_	_	CD	_	_	_	_	_
27	%	_	_	NN	_	_	_	_	_
28	was	_	_	VBD	_	_	_	_	_
29	sufficient	_	_	JJ	_	_	_	_	_
30	to	_	_	TO	_	_	_	_	_
31	induce	_	_	VB	_	_	_	_	_
32	a	_	_	DT	_	_	_	_	_
33	shift	_	_	NN	_	_	_	_	_
34	to	_	_	TO	_	_	_	_	_
35	a	_	_	DT	_	_	_	_	_
36	lower	_	_	JJR	_	_	_	_	_
37	risk	_	_	NN	_	_	_	_	_
38	category	_	_	NN	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	most	_	_	JJS	_	_	_	_	_
3	patients	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	NAFLD	_	_	NNP	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	associated	_	_	VBN	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	features	_	_	NNS	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	metabolic	_	_	JJ	_	_	_	_	_
12	syndrome	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	central	_	_	JJ	_	_	_	_	_
15	obesity	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	elevated	_	_	VBN	_	_	_	_	_
18	blood	_	_	NN	_	_	_	_	_
19	pressure	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	dyslipidemia	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	hyperglycemia	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	insulin	_	_	NN	_	_	_	_	_
27	resistance	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	Although	_	_	IN	_	_	_	_	_
2	these	_	_	DT	_	_	_	_	_
3	pathologies	_	_	NNS	_	_	_	_	_
4	can	_	_	MD	_	_	_	_	_
5	be	_	_	VB	_	_	_	_	_
6	addressed	_	_	VBN	_	_	_	_	_
7	by	_	_	IN	_	_	_	_	_
8	lifestyle	_	_	NN	_	_	_	_	_
9	interventions	_	_	NNS	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	daily	_	_	JJ	_	_	_	_	_
13	life	_	_	NN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	adherence	_	_	NN	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	necessary	_	_	JJ	_	_	_	_	_
19	lifestyle	_	_	NN	_	_	_	_	_
20	changes	_	_	NNS	_	_	_	_	_
21	is	_	_	VBZ	_	_	_	_	_
22	poor	_	_	JJ	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	resulting	_	_	VBG	_	_	_	_	_
25	in	_	_	IN	_	_	_	_	_
26	suboptimal	_	_	JJ	_	_	_	_	_
27	outcomes	_	_	NNS	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	contrast	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	pragmatic	_	_	JJ	_	_	_	_	_
6	programs	_	_	NNS	_	_	_	_	_
7	there	_	_	EX	_	_	_	_	_
8	is	_	_	VBZ	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	greater	_	_	JJR	_	_	_	_	_
11	benefit	_	_	NN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	more	_	_	RBR	_	_	_	_	_
15	substantial	_	_	JJ	_	_	_	_	_
16	weight	_	_	NN	_	_	_	_	_
17	loss	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	particularly	_	_	RB	_	_	_	_	_
20	at	_	_	IN	_	_	_	_	_
21	early	_	_	JJ	_	_	_	_	_
22	stages	_	_	NNS	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	intervention	_	_	NN	_	_	_	_	_
26	period	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Hence	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	periodic	_	_	JJ	_	_	_	_	_
4	fasting	_	_	NN	_	_	_	_	_
5	can	_	_	MD	_	_	_	_	_
6	significantly	_	_	RB	_	_	_	_	_
7	reduce	_	_	VB	_	_	_	_	_
8	weight	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	this	_	_	DT	_	_	_	_	_
12	effect	_	_	NN	_	_	_	_	_
13	can	_	_	MD	_	_	_	_	_
14	be	_	_	VB	_	_	_	_	_
15	maintained	_	_	VBN	_	_	_	_	_
16	over	_	_	IN	_	_	_	_	_
17	time	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	There	_	_	EX	_	_	_	_	_
2	are	_	_	VBP	_	_	_	_	_
3	several	_	_	JJ	_	_	_	_	_
4	concerns	_	_	NNS	_	_	_	_	_
5	about	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	adverse	_	_	JJ	_	_	_	_	_
8	effects	_	_	NNS	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	fasting	_	_	VBG	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_


1	Several	_	_	JJ	_	_	_	_	_
2	non-fatal	_	_	JJ	_	_	_	_	_
3	(	_	_	-LRB-	_	_	_	_	_
4	e.	_	_	FW	_	_	_	_	_
5	g.	_	_	FW	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	headache	_	_	NN	_	_	_	_	_
8	)	_	_	-RRB-	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	rarely	_	_	RB	_	_	_	_	_
11	fatal	_	_	JJ	_	_	_	_	_
12	(	_	_	-LRB-	_	_	_	_	_
13	e.	_	_	FW	_	_	_	_	_
14	g.	_	_	FW	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	ventricular	_	_	JJ	_	_	_	_	_
17	arrhythmia	_	_	NN	_	_	_	_	_
18	)	_	_	-RRB-	_	_	_	_	_
19	events	_	_	NNS	_	_	_	_	_
20	have	_	_	VBP	_	_	_	_	_
21	been	_	_	VBN	_	_	_	_	_
22	reported	_	_	VBN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	contrast	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	no	_	_	DT	_	_	_	_	_
5	severe	_	_	JJ	_	_	_	_	_
6	adverse	_	_	JJ	_	_	_	_	_
7	events	_	_	NNS	_	_	_	_	_
8	were	_	_	VBD	_	_	_	_	_
9	found	_	_	VBN	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	cohort	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	1422	_	_	CD	_	_	_	_	_
15	subjects	_	_	NNS	_	_	_	_	_
16	treated	_	_	VBN	_	_	_	_	_
17	with	_	_	IN	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	periodic	_	_	JJ	_	_	_	_	_
20	fasting	_	_	NN	_	_	_	_	_
21	lasting	_	_	VBG	_	_	_	_	_
22	4	_	_	CD	_	_	_	_	_
23	â€“	_	_	TO	_	_	_	_	_
24	21	_	_	CD	_	_	_	_	_
25	days	_	_	NNS	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_
28	Michalsen	_	_	NNP	_	_	_	_	_
29	et	_	_	FW	_	_	_	_	_
30	al.	_	_	FW	_	_	_	_	_
31	evaluated	_	_	VBD	_	_	_	_	_
32	the	_	_	DT	_	_	_	_	_
33	acceptance	_	_	NN	_	_	_	_	_
34	,	_	_	,	_	_	_	_	_
35	safety	_	_	NN	_	_	_	_	_
36	,	_	_	,	_	_	_	_	_
37	effects	_	_	NNS	_	_	_	_	_
38	on	_	_	IN	_	_	_	_	_
39	health-related	_	_	JJ	_	_	_	_	_
40	outcomes	_	_	NNS	_	_	_	_	_
41	,	_	_	,	_	_	_	_	_
42	and	_	_	CC	_	_	_	_	_
43	lifestyle	_	_	NN	_	_	_	_	_
44	adherence	_	_	NN	_	_	_	_	_
45	of	_	_	IN	_	_	_	_	_
46	fasting	_	_	VBG	_	_	_	_	_
47	therapy	_	_	NN	_	_	_	_	_
48	in	_	_	IN	_	_	_	_	_
49	different	_	_	JJ	_	_	_	_	_
50	chronic	_	_	JJ	_	_	_	_	_
51	internal	_	_	JJ	_	_	_	_	_
52	diseases	_	_	NNS	_	_	_	_	_
53	.	_	_	.	_	_	_	_	_


1	They	_	_	PRP	_	_	_	_	_
2	found	_	_	VBD	_	_	_	_	_
3	no	_	_	DT	_	_	_	_	_
4	serious	_	_	JJ	_	_	_	_	_
5	adverse	_	_	JJ	_	_	_	_	_
6	events	_	_	NNS	_	_	_	_	_
7	throughout	_	_	IN	_	_	_	_	_
8	their	_	_	PRP$	_	_	_	_	_
9	study	_	_	NN	_	_	_	_	_
10	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	study	_	_	NN	_	_	_	_	_
3	supports	_	_	VBZ	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	hypothesis	_	_	NN	_	_	_	_	_
6	that	_	_	IN	_	_	_	_	_
7	fasting	_	_	VBG	_	_	_	_	_
8	therapy	_	_	NN	_	_	_	_	_
9	provided	_	_	VBN	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	controlled	_	_	VBN	_	_	_	_	_
13	clinical	_	_	JJ	_	_	_	_	_
14	setting	_	_	NN	_	_	_	_	_
15	is	_	_	VBZ	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	safe	_	_	JJ	_	_	_	_	_
18	intervention	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	There	_	_	EX	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	large	_	_	JJ	_	_	_	_	_
5	body	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	evidence	_	_	NN	_	_	_	_	_
8	on	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	beneficial	_	_	JJ	_	_	_	_	_
11	effects	_	_	NNS	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	carbohydrate	_	_	NN	_	_	_	_	_
14	restriction	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	hypocaloric	_	_	JJ	_	_	_	_	_
17	diets	_	_	NNS	_	_	_	_	_
18	on	_	_	IN	_	_	_	_	_
19	NAFLD	_	_	NNP	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	also	_	_	RB	_	_	_	_	_
4	been	_	_	VBN	_	_	_	_	_
5	shown	_	_	VBN	_	_	_	_	_
6	that-at	_	_	IN	_	_	_	_	_
7	equal	_	_	JJ	_	_	_	_	_
8	levels	_	_	NNS	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	weight	_	_	NN	_	_	_	_	_
11	reduction-a	_	_	NN	_	_	_	_	_
12	carbohydrate-restricted	_	_	JJ	_	_	_	_	_
13	diet	_	_	NN	_	_	_	_	_
14	leads	_	_	VBZ	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	significantly	_	_	RB	_	_	_	_	_
18	greater	_	_	JJR	_	_	_	_	_
19	intrahepatic	_	_	JJ	_	_	_	_	_
20	triglyceride	_	_	NN	_	_	_	_	_
21	reduction	_	_	NN	_	_	_	_	_
22	than	_	_	IN	_	_	_	_	_
23	low-calorie	_	_	JJ	_	_	_	_	_
24	diet	_	_	NN	_	_	_	_	_
25	alone	_	_	RB	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	metabolic	_	_	JJ	_	_	_	_	_
3	advantage	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	carbohydrate	_	_	NN	_	_	_	_	_
6	restriction	_	_	NN	_	_	_	_	_
7	appears	_	_	VBZ	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	be	_	_	VB	_	_	_	_	_
10	related	_	_	VBN	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	more	_	_	RBR	_	_	_	_	_
14	pronounced	_	_	VBN	_	_	_	_	_
15	lipid	_	_	NN	_	_	_	_	_
16	oxidation	_	_	NN	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	enhanced	_	_	VBN	_	_	_	_	_
19	ketogenesis	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	recent	_	_	JJ	_	_	_	_	_
3	years	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	intermittent	_	_	JJ	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	periodic	_	_	JJ	_	_	_	_	_
8	fasting	_	_	NN	_	_	_	_	_
9	has	_	_	VBZ	_	_	_	_	_
10	gained	_	_	VBN	_	_	_	_	_
11	popularity	_	_	NN	_	_	_	_	_
12	as	_	_	IN	_	_	_	_	_
13	an	_	_	DT	_	_	_	_	_
14	alternative	_	_	NN	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	continuous	_	_	JJ	_	_	_	_	_
17	caloric	_	_	JJ	_	_	_	_	_
18	restriction	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	weight	_	_	NN	_	_	_	_	_
6	loss	_	_	NN	_	_	_	_	_
7	effects	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	periodic	_	_	JJ	_	_	_	_	_
10	fasting	_	_	NN	_	_	_	_	_
11	is	_	_	VBZ	_	_	_	_	_
12	associated	_	_	VBN	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	several	_	_	JJ	_	_	_	_	_
15	metabolic	_	_	JJ	_	_	_	_	_
16	benefits	_	_	NNS	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	including	_	_	VBG	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	improvement	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	lipid	_	_	JJ	_	_	_	_	_
23	profiles	_	_	NNS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	been	_	_	VBN	_	_	_	_	_
4	also	_	_	RB	_	_	_	_	_
5	shown	_	_	VBN	_	_	_	_	_
6	for	_	_	IN	_	_	_	_	_
7	intermittent	_	_	JJ	_	_	_	_	_
8	fasting	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	e.	_	_	FW	_	_	_	_	_
11	g.	_	_	FW	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	Ramadan	_	_	NNP	_	_	_	_	_
14	fasting	_	_	VBG	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	key	_	_	JJ	_	_	_	_	_
3	mechanism	_	_	NN	_	_	_	_	_
4	responsible	_	_	JJ	_	_	_	_	_
5	for	_	_	IN	_	_	_	_	_
6	many	_	_	JJ	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	these	_	_	DT	_	_	_	_	_
9	beneficial	_	_	JJ	_	_	_	_	_
10	effects	_	_	NNS	_	_	_	_	_
11	is	_	_	VBZ	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	metabolic	_	_	JJ	_	_	_	_	_
14	switch	_	_	NN	_	_	_	_	_
15	from	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	utilization	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	glycogenolysis-derived	_	_	JJ	_	_	_	_	_
20	glucose	_	_	NN	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	fatty	_	_	NN	_	_	_	_	_
23	acids	_	_	NNS	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	fatty	_	_	JJ	_	_	_	_	_
26	acid-derived	_	_	JJ	_	_	_	_	_
27	ketones	_	_	NNS	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	i.	_	_	FW	_	_	_	_	_
30	e.	_	_	FW	_	_	_	_	_
31	,	_	_	,	_	_	_	_	_
32	a	_	_	DT	_	_	_	_	_
33	fundamental	_	_	JJ	_	_	_	_	_
34	switch	_	_	NN	_	_	_	_	_
35	from	_	_	IN	_	_	_	_	_
36	lipid	_	_	NN	_	_	_	_	_
37	synthesis	_	_	NN	_	_	_	_	_
38	and	_	_	CC	_	_	_	_	_
39	fat	_	_	NN	_	_	_	_	_
40	storage	_	_	NN	_	_	_	_	_
41	to	_	_	TO	_	_	_	_	_
42	mobilization	_	_	NN	_	_	_	_	_
43	of	_	_	IN	_	_	_	_	_
44	fat	_	_	NN	_	_	_	_	_
45	in	_	_	IN	_	_	_	_	_
46	the	_	_	DT	_	_	_	_	_
47	form	_	_	NN	_	_	_	_	_
48	of	_	_	IN	_	_	_	_	_
49	free	_	_	JJ	_	_	_	_	_
50	fatty	_	_	NN	_	_	_	_	_
51	acids	_	_	NNS	_	_	_	_	_
52	and	_	_	CC	_	_	_	_	_
53	fatty	_	_	JJ	_	_	_	_	_
54	acid-derived	_	_	JJ	_	_	_	_	_
55	ketones	_	_	NNS	_	_	_	_	_
56	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	occurs	_	_	VBZ	_	_	_	_	_
3	between	_	_	IN	_	_	_	_	_
4	12	_	_	CD	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	36	_	_	CD	_	_	_	_	_
7	hours	_	_	NNS	_	_	_	_	_
8	after	_	_	IN	_	_	_	_	_
9	cessation	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	food	_	_	NN	_	_	_	_	_
12	consumption	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	Hyperinsulinemia	_	_	NN	_	_	_	_	_
2	suppresses	_	_	VBZ	_	_	_	_	_
3	ketogenesis	_	_	NN	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	therefore	_	_	RB	_	_	_	_	_
6	prolongs	_	_	VBZ	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	time	_	_	NN	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	switch	_	_	VB	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	cases	_	_	NNS	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	obesity	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	insulin	_	_	NN	_	_	_	_	_
17	resistance	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	T2DM	_	_	NNP	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Although	_	_	IN	_	_	_	_	_
2	there	_	_	EX	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	some	_	_	DT	_	_	_	_	_
5	evidence	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	impaired	_	_	JJ	_	_	_	_	_
8	ketogenesis	_	_	NN	_	_	_	_	_
9	during	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	progression	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	liver	_	_	NN	_	_	_	_	_
14	disease	_	_	NN	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	steatohepatitis	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	therapies	_	_	NNS	_	_	_	_	_
19	that	_	_	WDT	_	_	_	_	_
20	increase	_	_	VBP	_	_	_	_	_
21	hepatic	_	_	JJ	_	_	_	_	_
22	ketogenesis	_	_	NNS	_	_	_	_	_
23	are	_	_	VBP	_	_	_	_	_
24	expected	_	_	VBN	_	_	_	_	_
25	nonetheless	_	_	RB	_	_	_	_	_
26	to	_	_	TO	_	_	_	_	_
27	ameliorate	_	_	VB	_	_	_	_	_
28	NAFLD	_	_	NNP	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	data	_	_	NNS	_	_	_	_	_
3	provided	_	_	VBD	_	_	_	_	_
4	first	_	_	JJ	_	_	_	_	_
5	evidence	_	_	NN	_	_	_	_	_
6	that	_	_	IN	_	_	_	_	_
7	periodic	_	_	JJ	_	_	_	_	_
8	fasting	_	_	NN	_	_	_	_	_
9	leads	_	_	VBZ	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	clearance	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	liver	_	_	NN	_	_	_	_	_
15	fat	_	_	NN	_	_	_	_	_
16	:	_	_	:	_	_	_	_	_
17	fasting	_	_	VBG	_	_	_	_	_
18	significantly	_	_	RB	_	_	_	_	_
19	reduced	_	_	VBD	_	_	_	_	_
20	FLI	_	_	NNP	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	increased	_	_	VBD	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	proportion	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	patients	_	_	NNS	_	_	_	_	_
27	without	_	_	IN	_	_	_	_	_
28	NAFLD	_	_	NNP	_	_	_	_	_
29	(	_	_	-LRB-	_	_	_	_	_
30	FLI	_	_	NNP	_	_	_	_	_
31	<	_	_	SYM	_	_	_	_	_
32	30	_	_	CD	_	_	_	_	_
33	units	_	_	NNS	_	_	_	_	_
34	;	_	_	:	_	_	_	_	_


1	Figure	_	_	NN	_	_	_	_	_
2	2	_	_	CD	_	_	_	_	_


1	)	_	_	-RRB-	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	effects	_	_	NNS	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	fasting	_	_	VBG	_	_	_	_	_
5	therapy	_	_	NN	_	_	_	_	_
6	were	_	_	VBD	_	_	_	_	_
7	stronger	_	_	JJR	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	males	_	_	NNS	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	individuals	_	_	NNS	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	higher	_	_	JJR	_	_	_	_	_
15	baseline	_	_	NN	_	_	_	_	_
16	FLI	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	higher	_	_	JJR	_	_	_	_	_
19	GOT	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	higher	_	_	JJR	_	_	_	_	_
23	cholesterol	_	_	NN	_	_	_	_	_
24	levels	_	_	NNS	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Each	_	_	DT	_	_	_	_	_
2	additional	_	_	JJ	_	_	_	_	_
3	fasting	_	_	NN	_	_	_	_	_
4	day	_	_	NN	_	_	_	_	_
5	further	_	_	RBR	_	_	_	_	_
6	decreased	_	_	VBD	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	FLI	_	_	NNP	_	_	_	_	_
9	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	binary	_	_	JJ	_	_	_	_	_
3	logistic	_	_	JJ	_	_	_	_	_
4	regression	_	_	NN	_	_	_	_	_
5	showed	_	_	VBD	_	_	_	_	_
6	that	_	_	IN	_	_	_	_	_
7	every	_	_	DT	_	_	_	_	_
8	day	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	fasting	_	_	VBG	_	_	_	_	_
11	increase	_	_	NN	_	_	_	_	_
12	by	_	_	IN	_	_	_	_	_
13	40	_	_	CD	_	_	_	_	_
14	%	_	_	NN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	chance	_	_	NN	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	improve	_	_	VB	_	_	_	_	_
19	a	_	_	DT	_	_	_	_	_
20	manifest	_	_	JJ	_	_	_	_	_
21	fatty	_	_	JJ	_	_	_	_	_
22	liver	_	_	NN	_	_	_	_	_
23	(	_	_	-LRB-	_	_	_	_	_
24	FLI	_	_	NN	_	_	_	_	_
25	>	_	_	SYM	_	_	_	_	_
26	60	_	_	CD	_	_	_	_	_
27	)	_	_	-RRB-	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	switch	_	_	VB	_	_	_	_	_
30	to	_	_	TO	_	_	_	_	_
31	a	_	_	DT	_	_	_	_	_
32	lower	_	_	JJR	_	_	_	_	_
33	category	_	_	NN	_	_	_	_	_
34	of	_	_	IN	_	_	_	_	_
35	risk	_	_	NN	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	implies	_	_	VBZ	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	duration	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	fasting	_	_	NN	_	_	_	_	_
8	must	_	_	MD	_	_	_	_	_
9	be	_	_	VB	_	_	_	_	_
10	sufficient	_	_	JJ	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	influence	_	_	VB	_	_	_	_	_
13	fatty	_	_	JJ	_	_	_	_	_
14	liver	_	_	NN	_	_	_	_	_
15	positively	_	_	RB	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	should	_	_	MD	_	_	_	_	_
3	be	_	_	VB	_	_	_	_	_
4	taken	_	_	VBN	_	_	_	_	_
5	into	_	_	IN	_	_	_	_	_
6	account	_	_	NN	_	_	_	_	_
7	when	_	_	WRB	_	_	_	_	_
8	periodic	_	_	JJ	_	_	_	_	_
9	fasting	_	_	NN	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	considered	_	_	VBN	_	_	_	_	_
12	as	_	_	IN	_	_	_	_	_
13	treatment	_	_	NN	_	_	_	_	_
14	for	_	_	IN	_	_	_	_	_
15	NAFLD	_	_	NNP	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	As	_	_	IN	_	_	_	_	_
2	already	_	_	RB	_	_	_	_	_
3	mentioned	_	_	VBN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	insulin	_	_	NN	_	_	_	_	_
6	resistance	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	T2DM	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	development	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	NAFLD	_	_	NN	_	_	_	_	_
15	are	_	_	VBP	_	_	_	_	_
16	closely	_	_	RB	_	_	_	_	_
17	associated	_	_	VBN	_	_	_	_	_
18	conditions	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_
20	Taylor	_	_	NNP	_	_	_	_	_
21	et	_	_	FW	_	_	_	_	_
22	al.	_	_	FW	_	_	_	_	_
23	have	_	_	VBP	_	_	_	_	_
24	shown	_	_	VBN	_	_	_	_	_
25	that	_	_	IN	_	_	_	_	_
26	remission	_	_	NN	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	T2DM	_	_	NN	_	_	_	_	_
29	requires	_	_	VBZ	_	_	_	_	_
30	a	_	_	DT	_	_	_	_	_
31	decrease	_	_	NN	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	liver	_	_	NN	_	_	_	_	_
34	fat	_	_	NN	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	Patients	_	_	NNS	_	_	_	_	_
2	with	_	_	IN	_	_	_	_	_
3	T2DM	_	_	NNP	_	_	_	_	_
4	tend	_	_	VBP	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	have	_	_	VB	_	_	_	_	_
7	higher	_	_	JJR	_	_	_	_	_
8	FLI	_	_	NN	_	_	_	_	_
9	scores	_	_	NNS	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	but	_	_	CC	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	this	_	_	DT	_	_	_	_	_
14	study	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	we	_	_	PRP	_	_	_	_	_
17	could	_	_	MD	_	_	_	_	_
18	demonstrate	_	_	VB	_	_	_	_	_
19	that	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	fasting	_	_	VBG	_	_	_	_	_
22	intervention	_	_	NN	_	_	_	_	_
23	was	_	_	VBD	_	_	_	_	_
24	equally	_	_	RB	_	_	_	_	_
25	effective	_	_	JJ	_	_	_	_	_
26	in	_	_	IN	_	_	_	_	_
27	T2DM	_	_	NN	_	_	_	_	_
28	patients	_	_	NNS	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	in	_	_	IN	_	_	_	_	_
31	non-diabetic	_	_	JJ	_	_	_	_	_
32	subjects	_	_	NNS	_	_	_	_	_
33	in	_	_	IN	_	_	_	_	_
34	terms	_	_	NNS	_	_	_	_	_
35	of	_	_	IN	_	_	_	_	_
36	FLI	_	_	NNP	_	_	_	_	_
37	,	_	_	,	_	_	_	_	_
38	although	_	_	IN	_	_	_	_	_
39	the	_	_	DT	_	_	_	_	_
40	improvement	_	_	NN	_	_	_	_	_
41	of	_	_	IN	_	_	_	_	_
42	other	_	_	JJ	_	_	_	_	_
43	parameters	_	_	NNS	_	_	_	_	_
44	(	_	_	-LRB-	_	_	_	_	_
45	e.	_	_	NN	_	_	_	_	_
46	g.	_	_	NN	_	_	_	_	_
47	,	_	_	,	_	_	_	_	_
48	HDL	_	_	NNP	_	_	_	_	_
49	,	_	_	,	_	_	_	_	_
50	LDL	_	_	NNP	_	_	_	_	_
51	,	_	_	,	_	_	_	_	_
52	and	_	_	CC	_	_	_	_	_
53	AP	_	_	NNP	_	_	_	_	_
54	)	_	_	-RRB-	_	_	_	_	_
55	was	_	_	VBD	_	_	_	_	_
56	not	_	_	RB	_	_	_	_	_
57	as	_	_	RB	_	_	_	_	_
58	complete	_	_	JJ	_	_	_	_	_
59	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	results	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	line	_	_	NN	_	_	_	_	_
6	with	_	_	IN	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	previous	_	_	JJ	_	_	_	_	_
9	study	_	_	NN	_	_	_	_	_
10	on	_	_	IN	_	_	_	_	_
11	periodic	_	_	JJ	_	_	_	_	_
12	fasting	_	_	NN	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	T2DM	_	_	NNP	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	Liver	_	_	NN	_	_	_	_	_
2	enzymes	_	_	NNS	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	insulin	_	_	NN	_	_	_	_	_
5	resistance	_	_	NN	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	cholesterol	_	_	NN	_	_	_	_	_
9	levels	_	_	NNS	_	_	_	_	_
10	are	_	_	VBP	_	_	_	_	_
11	related	_	_	VBN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	NAFLD	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	results	_	_	NNS	_	_	_	_	_
3	supported	_	_	VBD	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	correlation	_	_	NN	_	_	_	_	_
6	between	_	_	IN	_	_	_	_	_
7	changes	_	_	NNS	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	FLI	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	changes	_	_	NNS	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	liver	_	_	NN	_	_	_	_	_
14	enzymes	_	_	NNS	_	_	_	_	_
15	(	_	_	-LRB-	_	_	_	_	_
16	GGT	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	GOT	_	_	NN	_	_	_	_	_
20	)	_	_	-RRB-	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	lipid	_	_	JJ	_	_	_	_	_
23	parameters	_	_	NNS	_	_	_	_	_
24	(	_	_	-LRB-	_	_	_	_	_
25	TG	_	_	NN	_	_	_	_	_
26	)	_	_	-RRB-	_	_	_	_	_
27	after	_	_	IN	_	_	_	_	_
28	fasting	_	_	VBG	_	_	_	_	_
29	intervention	_	_	NN	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	although	_	_	IN	_	_	_	_	_
32	this	_	_	DT	_	_	_	_	_
33	was	_	_	VBD	_	_	_	_	_
34	limited	_	_	VBN	_	_	_	_	_
35	to	_	_	TO	_	_	_	_	_
36	subjects	_	_	NNS	_	_	_	_	_
37	without	_	_	IN	_	_	_	_	_
38	T2DM	_	_	NNP	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_

